Aeterna Zentaris Appoints Chief Commercial Officer, Reaffirming New Company Vision

About this update from Cosciens Biopharma Inc.

[{"type":"text","content":"\n\n\nAll amounts are in US dollars\n\n\nQUÉBEC CITY, Nov. 1, 2013 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ:\n AEZS) (TSX: AEZ) (the \"Company\") today announced the appointment of\n Jude Dinges as Senior Vice President, Chief Commercial Officer, thus\n reaffirming its new vision of becoming a specialty biopharmaceutical\n commercially operating company.\n\n\n\"Over the last few months, we have conducted an in-depth review of our\n R&D and corporate activities. This has led to a comprehensive strategic\n growth plan focused on achieving our goal of transforming Aeterna\n Zentaris into a biopharmaceutical operating company through the\n commercialization of our pipeline, as well as through actively pursuing\n in-licensing and acquisition opportunities\", said David Dodd, President\n and CEO of Aeterna Zentaris. \"Jude's appointment is in line with this\n new vision. His more than 30 years experience in pharmaceutical and\n biologics commercial development will be very valuable as we are in the\n process of bringing macimorelin acetate to market as the first approved\n oral product for evaluating growth hormone deficiency in adults. He\n will also be responsible for future commercial opportunities with a\n view of ensuring sustained growth. We are delighted that Jude is\n joining our management team, and we look forward to his contributions\n to our growth and development.\"\n\n\nJude Dinges added, \"I'm very excited to join the Aeterna Zentaris team\n at this important time in its history. With a near-term NDA filing, a\n promising oncology pipeline and a talented leadership team, I feel\n Aeterna Zentaris holds great promise as a commercial entity, offering\n solutions to the unmet medical needs of patients and the healthcare\n professionals who serve them.\"\n\n\nNew Strategic Vision\n\n\n\n\nFocus on the successful development and commercialization of Company\n pipeline:\n\n\n\nMacimorelin acetate (AEZS-130)\n\n\n\n\nSubmission of NDA to the FDA as the first approved oral product for the\n evaluation of adult growth hormone deficiency\n\n\n\nPreparation for its commercial launch (sales and marketing strategy)\n\n\n\nCommercial launch and brand development\n\n\n\nZoptarelin doxorubicin (AEZS-108)\n\n\n\n\nIncreased efforts regarding patient enrollment for Phase 3 ZoptEC (Zoptarelin doxorubicin in Endometrial C...

More updates from Cosciens Biopharma Inc.